A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Patricia Martin‐Rodríguez(Universidad de Las Palmas de Gran Canaria), Leandro Fernández‐Pérez(Universidad de Las Palmas de Gran Canaria)

Frontiers in Pharmacology

January 9, 2019

10.3389/fphar.2018.01546

Cited by 12

Related Papers

CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

|Oncotarget|2016|13